Abstract
Organophosphates are used as pesticides or misused as warfare nerve agents. Exposure to them can be fatal and death is usually caused by respiratory arrest. For almost six decades, pyridinium oximes represent a therapeutic tool used for the management of poisoning with organophosphorus (OP) compounds. However, these compounds possess several drawbacks. Firstly, they are inefficient in the restoration of brain acetylcholinesterase (AChE) activity due to a hard blood-brain barrier penetration. Secondly, there is no broad-spectrum AChE reactivator. Lastly, none of the oximes can reactivate “aged” AChE. In this context, uncharged reactivators represent a new hope in a way of increased bioavailability in the central compartment and better therapeutic management of the OP poisoning.
Keywords: Acetylcholinesterase, HI-6, organophosphorus compounds, pyridinium oximes, pralidoxime, reactivator, trimedoxime, uncharged reactivator.
Mini-Reviews in Medicinal Chemistry
Title:From Pyridinium-based to Centrally Active Acetylcholinesterase Reactivators
Volume: 14 Issue: 3
Author(s): Jan Korabecny, Ondrej Soukup, Rafael Dolezal, Katarina Spilovska, Eugenie Nepovimova, Martin Andrs, Thuy Duong Nguyen, Daniel Jun, Kamil Musilek, Marta Kucerova-Chlupacova and Kamil Kuca
Affiliation:
Keywords: Acetylcholinesterase, HI-6, organophosphorus compounds, pyridinium oximes, pralidoxime, reactivator, trimedoxime, uncharged reactivator.
Abstract: Organophosphates are used as pesticides or misused as warfare nerve agents. Exposure to them can be fatal and death is usually caused by respiratory arrest. For almost six decades, pyridinium oximes represent a therapeutic tool used for the management of poisoning with organophosphorus (OP) compounds. However, these compounds possess several drawbacks. Firstly, they are inefficient in the restoration of brain acetylcholinesterase (AChE) activity due to a hard blood-brain barrier penetration. Secondly, there is no broad-spectrum AChE reactivator. Lastly, none of the oximes can reactivate “aged” AChE. In this context, uncharged reactivators represent a new hope in a way of increased bioavailability in the central compartment and better therapeutic management of the OP poisoning.
Export Options
About this article
Cite this article as:
Korabecny Jan, Soukup Ondrej, Dolezal Rafael, Spilovska Katarina, Nepovimova Eugenie, Andrs Martin, Nguyen Duong Thuy, Jun Daniel, Musilek Kamil, Kucerova-Chlupacova Marta and Kuca Kamil, From Pyridinium-based to Centrally Active Acetylcholinesterase Reactivators, Mini-Reviews in Medicinal Chemistry 2014; 14 (3) . https://dx.doi.org/10.2174/1389557514666140219103138
DOI https://dx.doi.org/10.2174/1389557514666140219103138 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multiple Hsp70 Isoforms in the Eukaryotic Cytosol: Mere Redundancy or Functional Specificity?
Current Genomics Chelating Agents for the Treatment of Systemic Iron Overload
Current Medicinal Chemistry New Insights on the Perturbations of T Cell Cycle During HIV Infection
Current Medicinal Chemistry Antifungal Proteins: Potent Candidate for Inhibition of Pathogenic Fungi
Current Bioactive Compounds Recent Advances in Flavivirus Antiviral Drug Discovery and Vaccine Development
Recent Patents on Anti-Infective Drug Discovery Anti-Inflammatory Drug Targeting in Asthma. Should Inhaled Corticosteroids Reach the Small Airways?
Current Drug Therapy Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Current Cancer Therapy Reviews Pharmaceutical Strategies for Activating Sirtuins
Current Pharmaceutical Design PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry Imaging of Visceral Adipose Tissue: An Emerging Diagnostic Tool and Therapeutic Target
Current Drug Targets - Cardiovascular & Hematological Disorders Intrauterine Intervention for the Treatment of Fetal Growth Restriction
Current Pediatric Reviews Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Central Arterial Aging and Angiotensin II Signaling
Current Hypertension Reviews Interaction of Different Proteins with GABA<sub>A</sub> Receptor and their Modulatory Effect on Inhibitory Neural Transmission Leads to Epilepsy
CNS & Neurological Disorders - Drug Targets The Management of Metastatic Bone Disease with the Combination of Bisphosphonates and Radiotherapy: From Theory to Clinical Practice
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in Anxiety Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Biomarkers for Predicting the Immunomodulatory Properties of Probiotics
Recent Patents on Biomarkers Recent Development in Identification of Potential Novel Therapeutic Targets Against Trypanosomatids
Current Topics in Medicinal Chemistry Antibody-Drug Conjugate Targets
Current Cancer Drug Targets